AU2025217250A1 — Dosing of KRAS inhibitor for treatment of cancers

USPTO Abstract

#$%^&*AU2025217250A120250828.pdf##### DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS Abstract Provided herein are methods of administering a KRAS G 12C inhibitor, namely AMG-510, to a cancer subject. CA19-9 and CEA Biomarkers. DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS Abstract RI R* S. N Q R² N N Rb N Rª 0 Ris (I) Provided herein are methods of administering a KRAS G 12C inhibitor, namely AMG-510, to a cancer subject. CA19-9 and CEA Biomarkers. 20 25 21 72 50 12 A ug 2 02 5 D O S I N G O F K R A S I N H I B I T O R F O R T R E A T M E N T O F C A N C E R S 2 0 2 5 2 1 7 2 5 0 1 2 2 0 2 5 A u g A b s t r a c t R I R * S . N Q R ² N N R N R ª 0 i s (I ) P r o v i d e d h e r e i n a r e m e t h o d s o f a d m i n i s t e r i n g a K R A S G 1 2 C i n h i b i t o r , n a m e l y A M G - 5 1 0 , t o a c a n c e r s u b j e c t . C A 1 9 - 9 a n d C E A B i o m a r k e r s .